SHPA releases pharmacy standard for heart disease
The Society of Hospital Pharmacists of Australia (SHPA) has released the pharmacy practice standard for treating cardiovascular disease, recommending patient to pharmacist ratios and quality improvement indicators specific to specialist cardiology pharmacists, and detailing how to add innovative, emerging cardiology services to core practice to ensure best care.
SHPA Cardiology Chair Adam Livori said the standards highlight present and future pathways for cardiology pharmacy services — ‘from the cath lab to rehab’.
“Pharmacists can provide a wealth of knowledge and assistance to patient care, directly improve clinical outcomes and are an asset to the multidisciplinary team as supported by national and international guidelines.
“These new standards define cardiology pharmacy services, guide implementation and encourage adaptability of models of care to address the dynamic landscape of health care across the system.”
Lead author and SHPA Cardiology Leadership Committee member Joanna Pizzi said the new standard reflects the broad range of cardiac interventions and care settings in Australia.
“Our recommended patient to pharmacist ratios range from 8:1 in areas of medical intervention and review, such as cardiac rehabilitation centres or heart failure clinics, to 20:1 for patients hospitalised for lower-risk procedures.
Similarly, SHPA’s new ‘Essential and emerging cardiology services for pharmacists’ table details 43 care activities applicable to all settings — as well as inpatient, outpatient and operational settings specifically — which, when led by specialist cardiology pharmacists, will help ensure optimal outcomes for patients with heart disease.
“As the number of Australians requiring hospitalisation continues to grow and cases increase in complexity, this standard also details key knowledge, skills and experiential learning for cardiology pharmacists.
“By combining with guidance on tailoring quality indicators from leading Australian and European sources to target and achieve the best outcomes for all patient groups, this standard seeks to help ensure sustainability and performance improvement in this critical workforce, to the benefit of all Australians requiring acute cardiovascular care.”
SHPA Chief Executive Kristin Michaels said cardiovascular disease is the leading cause of death and disease burden in Australia and worldwide.
“It is important to highlight pathways to future-focused cardiology pharmacy services in all care settings to ensure equity of access for Australians at risk of cardiovascular disease, which disproportionately affects older Australians and Indigenous populations.”
The standard of practice in cardiology for pharmacy services leads the February issue of SHPA’s flagship Journal of Pharmacy Practice and Research (JPPR). The issue is available for free, as always, to SHPA members.
High blood pressure costs Australia $1.2bn a year
Australia’s high blood pressure problem costs the country AU$1.2bn a year, with patients...
'Calming agent' could help treat diabetic heart disease
Heart conditions like atherosclerosis, heart attacks and heart failure are said to be the leading...
New public health campaign to improve pregnancy outcomes
The Preterm Birth Prevention campaign 'See, Stop, Scan' aims to promote engagement...
